GYRE GYRE THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, GYRE THERAPEUTICS INC reported revenue of $29.1M (down 2.1% from a year earlier), net income of −$14.3M and diluted EPS of −$0.12; over the last four quarters revenue was $116M and net income −$25.7M; for the fiscal year ended December 2025 revenue was $117M, up 10.2% on the year before.
GYRE annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $117M, gross profit n/a, operating income $11.5M, net income $9.88M (margin 8.5%), EPS $0.02
- Fiscal year ended Dec 2024: revenue $106M, gross profit $102M, operating income $16.2M, net income $17.9M (margin 16.9%), EPS $0.05
- Fiscal year ended Dec 2023: revenue $113M, gross profit $109M, operating income −$67.2M, net income −$85.5M (margin -75.3%), EPS −$1.41
- Fiscal year ended Dec 2022: revenue $102M, gross profit $97.5M, operating income $9.20M, net income $4.31M (margin 4.2%), EPS $0.03
- Fiscal year ended Dec 2021: revenue $7.34M, gross profit n/a, operating income −$87.9M, net income −$87.9M (margin -1198.3%), EPS −$2.87
GYRE quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $29.1M (down 2.1% year over year), net income −$14.3M, EPS −$0.12
- Quarter ended Mar 31, 2026: revenue $22.5M (up 2.1% year over year), net income −$18.6M, EPS −$0.10
- Quarter ended Dec 31, 2025 (from the annual report): revenue $34.2M (up 22.8% year over year), net income $1.24M, EPS $0.02
- Quarter ended Sep 30, 2025: revenue $30.6M (up 19.9% year over year), net income $5.94M, EPS $0.03
- Quarter ended Jun 30, 2025: revenue $29.7M (up 17.9% year over year), net income −$2.24M, EPS −$0.03
- Quarter ended Mar 31, 2025: revenue $22.1M (down 18.8% year over year), net income $4.94M, EPS $0.00
- Quarter ended Dec 31, 2024 (from the annual report): revenue $27.9M (up 2.7% year over year), net income $569K, EPS $0.00
- Quarter ended Sep 30, 2024: revenue $25.5M (down 20.5% year over year), net income $2.86M, EPS $0.01
- Quarter ended Jun 30, 2024: revenue $25.2M (down 14.0% year over year), net income $4.54M, EPS $0.01
- Quarter ended Mar 31, 2024: revenue $27.2M (up 9.0% year over year), net income $9.94M, EPS $0.03
- Quarter ended Dec 31, 2023 (from the annual report): revenue $27.1M, net income −$101M, EPS −$1.51
- Quarter ended Sep 30, 2023: revenue $32.0M, net income $7.51M, EPS $0.05
- Quarter ended Jun 30, 2023: revenue $29.3M, net income $3.77M, EPS $0.02
- Quarter ended Mar 31, 2023: revenue $24.9M (up 3039.9% year over year), net income $4.22M, EPS $0.03
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$27.9M, EPS −$0.99
- Quarter ended Sep 30, 2022: revenue n/a, net income −$4.88M, EPS −$0.16
- Quarter ended Jun 30, 2022: revenue n/a, net income $51.6M, EPS $1.64
- Quarter ended Mar 31, 2022: revenue $794K (down 45.9% year over year), net income −$14.5M, EPS −$0.46
- Quarter ended Dec 31, 2021 (from the annual report): revenue $2.44M, net income −$20.3M, EPS −$0.64
- Quarter ended Sep 30, 2021: revenue $2.30M, net income −$25.2M, EPS −$0.80
GYRE cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow $1.01M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$3.64M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow $25.9M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow $10.7M, share buybacks n/a, dividends $0.24 per share
- Fiscal year ended Dec 2021: operating cash flow −$83.8M, share buybacks n/a
GYRE balance sheet
- Jun 30, 2026: cash $43.3M, total assets $199M, total liabilities $34.3M, shareholders' equity $108M
- Mar 31, 2026: cash $37.5M, total assets $162M, total liabilities $25.0M, shareholders' equity $101M
- Dec 31, 2025: cash $49.2M, total assets $220M, total liabilities $31.4M, shareholders' equity $62.5M
- Sep 30, 2025: cash $40.4M, total assets $159M, total liabilities $22.0M, shareholders' equity $102M
- Jun 30, 2025: cash $36.5M, total assets $153M, total liabilities $23.2M, shareholders' equity $92.0M
- Mar 31, 2025: cash $15.0M, total assets $130M, total liabilities $25.5M, shareholders' equity $68.1M
- Dec 31, 2024: cash $11.8M, total assets $125M, total liabilities $27.0M, shareholders' equity $63.3M
- Sep 30, 2024: cash $15.9M, total assets $125M, total liabilities $26.8M, shareholders' equity $63.2M
What is GYRE's revenue?
GYRE THERAPEUTICS INC reported $116M of revenue over its last four quarters, through June 30, 2026.
Is GYRE profitable?
No. GYRE THERAPEUTICS INC lost $25.7M over the last four quarters.
What is GYRE's EPS?
Diluted earnings per share over the last four quarters were −$0.17; −$0.12 in the latest quarter.
Does GYRE pay a dividend?
GYRE THERAPEUTICS INC paid $0.24 per share in dividends in the fiscal year ended December 2022.